The investment bank Goldman Sachs asks a revealing question.

Is curing patients a sustainable business model?

We need a new system.

We need a new society.

We need to demand that which may have sounded impossible even a few weeks ago,

but is not only realizable, but an imperative necessity. Andy. The We are very excited to have Professor Richard Wolfe join us for a regular weekly segment

where we discuss the biggest stories relating to the economy, the state of the working

class, and the crimes of big business. I'm Nicole Roussel,

sitting in for your host, Brian Becker. The Socialist Program brings you content several days a week

thanks to the support of our patrons at patreon.com slash the Socialist Program. We appreciate all

of your support and encourage you to become a patron today if you enjoy listening to the show.

Richard Wolf is the co-founder of the organization Democracy at Work and the author of many

books, including Understanding Capitalism, which is available at democracy at work.info.

All right, Richard, this wild story that's been going around, the headline, as I read in the

introduction, is Goldman Sachs asks in biotech research

report, is curing patients a sustainable business model? The idea that we as a society wouldn't

put our time, efforts, and resources into curing patients is an insane idea. But of course,

the answer to this question, is it a sustainable business model, is actually, no, it's not under capitalism.

I want to read just a few sentences from the report. It goes, the potential to deliver, quote-unquote, one-shot cures is one of the most attractive.

While this proposition carries tremendous value for patients and society, it could represent a challenge for genome medicine developers looking

for sustained cash flow, unquote. Under capitalism, as we all know, profit is the motive for the

capitalist, the ones who own everything. And so this analyst isn't really saying anything

...